Researchers discover new inhibitor drug combination for rare form of cancer
Waldenström macroglobulinemia (WM), a rare form of lymphoma, does not have any known cure and only one FDA-approved treatment making […]
» Read moreHome »
A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically […] In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP […]
Enhancing immune checkpoint inhibitor therapy using treatment combination
PARP inhibitor improves progression-free survival in patients with advanced breast cancers
